Millennium Pharmacon International (SDPC) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Millennium Pharmacon International IDR 664, price IDR 191, upside +247.8%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Millennium Pharmacon International for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
PT Millennium Pharmacon International Tbk engages in the distribution of prescription and non-prescription medicines and medical devices in Indonesia. It also engages in trading and software equipment business.
Show more
PT Millennium Pharmacon International Tbk engages in the distribution of prescription and non-prescription medicines and medical devices in Indonesia. It also engages in trading and software equipment business. The company was formerly known as PT NVPD Soedarpo Corporation Tbk and changed its name to PT Millennium Pharmacon International Tbk in February 1990. The company was founded in 1952 and is headquartered in Jakarta Selatan, Indonesia. PT Millennium Pharmacon International Tbk is a subsidiary of Pharmaniaga International Corporation Sdn. Bhd.
Stock analysis
Millennium Pharmacon International (SDPC) currently trades at 191.00 IDR, while our model-based Fair Value estimate is 664.30 IDR, implying the stock looks roughly 71.2% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 1,550 IDR per share, and 22 of the 25 models we run sit above the 191.00 IDR price.
Bear case: the Asset-Based group reads lowest at 165.88 IDR, and 3 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: 498.22 IDR (bear) to 830.37 IDR (bull), the price of 191.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Millennium Pharmacon International reported revenue of 4.1T IDR in FY2025 versus 3.0T IDR in FY2021, a compound +8.3%/yr. Reported net income was 38.5B IDR in FY2025, compounding +41.6%/yr from FY2021.
Key figures
Market cap 243B IDR (≈ $13.6M) · P/E ratio 6.4 · P/S ratio 0.06 · EPS (TTM) 30.01 IDR · Dividend yield 1.1% · Net margin 0.9% · Return on equity 12.4% · Return on assets (EBIT) 5.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at 248%, SDPC screens cheaper than that median.
Fair Value models
Bear 498.22 IDRFair Value 664.30 IDRBull 830.37 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (22.69 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Start year 2020 (pandemic). Over 10 years: +9.2% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +18.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.6%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.37.3% vs 7.3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 3%
Start year 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 57% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +13.0% a year for the price.
Compare Millennium Pharmacon International with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 78 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (TTM)12.4% · Top 25%
Return on assets3.6% · Above median
Net margin (TTM)0.9% · Below median
Operating margin (TTM)2.8% · Above median
Growth and dividend
Revenue growth3.9% · Above median
Dividend yield (TTM)1.1% · Below median
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Millennium Pharmacon International Fair Value". https://www.fairvalue-calculator.com/stock/SDPC
Frequently asked questions
Is Millennium Pharmacon International (SDPC) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 664.30 IDR versus a price of 191.00 IDR, about +248% upside (undervalued).
What is the fair value of SDPC?
Our model-based fair value for Millennium Pharmacon International is 664.30 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 191.00 IDR.
What is the quality score of SDPC?
Millennium Pharmacon International has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Millennium Pharmacon International (SDPC)?
Our model-based price target is the fair value of 664.30 IDR (as of Sep 24, 2026) from 25 valuation models. Cautious scenario 498.22 IDR, optimistic scenario 830.37 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Millennium Pharmacon International stock forecast for 2026?
Our models put fair value at 664.30 IDR, about +248% upside versus a price of 191.00 IDR (undervalued). Cautious scenario 498.22 IDR, optimistic scenario 830.37 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Millennium Pharmacon International (SDPC)?
Millennium Pharmacon International reported trailing-twelve-month revenue of about 4.1T IDR (latest available figure, as of Sep 24, 2026).
Does Millennium Pharmacon International pay a dividend?
Millennium Pharmacon International currently shows a dividend yield of about 1.11% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Millennium Pharmacon International (SDPC)?
For today's price to be fair in a discounted-cash-flow model, Millennium Pharmacon International would have to grow free cash flow by +15.9 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of SDPC use?
Our models discount Millennium Pharmacon International at 10.5 %: a base by market capitalisation (nano), damped by beta 0.35, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Millennium Pharmacon International that is +15.9 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Millennium Pharmacon International (SDPC) delivered so far?
Over the past 5 years revenue at Millennium Pharmacon International grew +9.2 % a year. The price currently implies +15.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Millennium Pharmacon International (SDPC) growing?
The median revenue growth in the sector is +5.0 % a year. That is the yardstick for the growth priced into Millennium Pharmacon International (+15.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Millennium Pharmacon International (SDPC)?
The free-cash-flow yield on the price is 16.03 %: that much free cash flow Millennium Pharmacon International produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Millennium Pharmacon International (SDPC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Millennium Pharmacon International it is 664.30 IDR per share (as of Sep 24, 2026), against a price of 191.00 IDR. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Millennium Pharmacon International stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SDPC trades below its calculated fair value: price 191.00 IDR, fair value 664.30 IDR, a gap of about +248% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SDPC?
No. The price is what the market pays today (191.00 IDR); the fair value is what the company's own numbers justify (664.30 IDR). For Millennium Pharmacon International the two are 473.30 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Millennium Pharmacon International worth?
The market values Millennium Pharmacon International at about 243B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 191.00 IDR; our models calculate a fair value of 664.30 IDR per share.
What do the bullish and bearish scenarios say about SDPC?
Our models span a range for Millennium Pharmacon International: cautious scenario 498.22 IDR, base 664.30 IDR, optimistic 830.37 IDR per share (as of Sep 24, 2026, price 191.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SDPC?
Millennium Pharmacon International trades at a price-to-earnings ratio of 6.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 664.30 IDR is built from several models across several years. Other multiples: P/B 0.8, P/S 0.1, EV/EBITDA 2.0.
How solid is the balance sheet of Millennium Pharmacon International (SDPC)?
Balance-sheet figures for Millennium Pharmacon International (as of Sep 24, 2026): return on equity 12.4%, debt of 0.17 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is SDPC from its 52-week high?
Millennium Pharmacon International trades at 191.00 IDR, about 8% below its 52-week high of 208.00 IDR and 45% above the low of 131.56 IDR (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 664.30 IDR is for.
Which stocks are comparable to Millennium Pharmacon International?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Millennium Pharmacon International stock attractive at the current price?
The data as of Sep 24, 2026: price 191.00 IDR, calculated fair value 664.30 IDR (+248%), Quality Score 47/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SDPC calculated?
We run Millennium Pharmacon International through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 664.30 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Millennium Pharmacon International currently trades 71 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Millennium Pharmacon International (SDPC)?
The closing price on Oct 2, 2026 was 191.00 IDR. Our model-based fair value is 664.30 IDR, about +248% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Millennium Pharmacon International right now?
The price is below even our cautious bear case (498.22 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Millennium Pharmacon International (SDPC) come from?
Earnings per share at Millennium Pharmacon International grew +6.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.9 %, EBIT margin +2.2 %, tax rate +0.4 %, residual (interest, one-offs) +0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Millennium Pharmacon International
How large is the market capitalisation of Millennium Pharmacon International (SDPC)?
The market capitalisation of Millennium Pharmacon International is 243B IDR (≈ $13.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Millennium Pharmacon International (SDPC)?
The price-to-sales ratio of Millennium Pharmacon International is 0.06 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Millennium Pharmacon International (SDPC)?
Earnings per share at Millennium Pharmacon International are 30.01 IDR (price ÷ EPS = P/E 6.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Millennium Pharmacon International (SDPC)?
The dividend yield of Millennium Pharmacon International is 1.1% (payout 7.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Millennium Pharmacon International (SDPC)?
The net margin of Millennium Pharmacon International is 0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Millennium Pharmacon International (SDPC)?
The return on equity (ROE) of Millennium Pharmacon International is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Millennium Pharmacon International (SDPC)?
On an EBIT basis the return on assets of Millennium Pharmacon International is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Millennium Pharmacon International (SDPC)?
The operating margin of Millennium Pharmacon International is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Millennium Pharmacon International (SDPC)?
Revenue at Millennium Pharmacon International is growing +3.9% versus a year earlier (3y avg +8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Millennium Pharmacon International (SDPC)?
Earnings per share at Millennium Pharmacon International are growing −2.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Millennium Pharmacon International (SDPC) carry?
The net debt of Millennium Pharmacon International is 746B IDR (fiscal year 2025, ≈ 19.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Millennium Pharmacon International in the live analysis
One click puts Millennium Pharmacon International on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
